Quantum BioPharma (NASDAQ: QNTM) has taken a significant step toward advancing its lead drug candidate for multiple sclerosis (MS) by entering into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific. The agreement, announced via NEWMEDIAWIRE, initiates formal start-up activities for a Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) following FDA clearance to proceed. Thermo Fisher will provide study start-up and related clinical research services through its PPD Clinical Research Business.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class new chemical entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism distinguishes Lucid-MS from existing MS therapies, which primarily modulate the immune system rather than directly protect myelin.
The importance of this announcement lies in its potential to address a critical gap in MS treatment. Progressive forms of MS, including primary progressive and secondary progressive MS, currently have limited therapeutic options and are characterized by relentless neurological decline. By targeting the underlying mechanism of myelin degradation, Lucid-MS aims to prevent or reverse damage to the myelin sheath that insulates nerve fibers. If successful, this approach could offer a disease-modifying therapy that slows or halts disability progression, a goal that has eluded many previous MS drug development efforts.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. Preclinical models have shown the compound to both prevent and reverse myelin degradation, providing a strong rationale for clinical testing. The Phase 2 trial will be a crucial test of whether these promising preclinical findings translate into meaningful benefits for patients. The involvement of Thermo Fisher’s PPD clinical research business adds operational expertise and credibility to the study’s execution.
For investors and the biopharmaceutical industry, this agreement signals tangible progress for Quantum BioPharma’s pipeline. The company’s ability to advance Lucid-MS into Phase 2 following FDA clearance demonstrates regulatory confidence and positions Quantum as a serious player in the neuroprotective space. The full press release can be accessed at https://ibn.fm/CZH9U, and ongoing updates regarding QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Beyond MS, Quantum BioPharma maintains a portfolio that includes UNBUZZD, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026, along with royalty rights. However, the Lucid-MS program represents the company’s most direct foray into a large, high-unmet-need market. The global MS therapeutics market is valued in the tens of billions of dollars, and a successful neuroprotective agent could capture significant share, particularly among patients with progressive disease who respond poorly to current treatments.
The study start-up agreement does not guarantee trial success, but it marks the transition from planning to execution. As the Phase 2 trial gets underway, the MS community and investors will be watching closely for data that could validate PAD2 inhibition as a novel therapeutic strategy. The outcome may have broad implications for how MS is treated, shifting focus from immune modulation alone to direct neuroprotection. For more details, refer to the official announcement on www.newmediawire.com.
